Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. For hepatitis B it may be used alone. It is given by injection under the skin.
Read the full article on WikipediaChronic hepatitis C infection Clinical criteria: Treatment criteria: Must be treated in an accredited treatment centre. Population criteria: Patient must be at least 18 years of age, AND Patient must not be pregnant or breastfeeding, and must be using an effective form of contraception if female and of child-bearing age. Patient must have compensated liver disease, AND Patient must not have received prior interferon alfa or peginterferon alfa treatment for hepatitis C, AND Patient must have a contraindication to ribavirin, AND The treatment must cease unless the results of an HCV RNA quantitative assay at week 12 (performed at the same laboratory using the same test) show that plasma HCV RNA has become undetectable or the viral load has decreased by at least a 2 log drop, AND The treatment must be limited to a maximum duration of 48 weeks. Evidence of chronic hepatitis C infection (repeatedly anti-HCV positive and HCV RNA positive) must be documented in the patient's medical records.
Working under the parallel aged-care framework? Aged-care equivalent →